中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
5期
45-47
,共3页
胃癌%化疗%三维适形放疗
胃癌%化療%三維適形放療
위암%화료%삼유괄형방료
Gastric carcinoma%Chemotherapy%Dimensional conformal radiotherapy
目的 观察同步放化疗治疗进展期胃癌根治术后患者的临床疗效和安全耐受性.方法 将96例根治术后的进展期胃癌患者随机分为观察组(52例)和对照组(44例).观察组根治术后应用三维适形放疗联合化疗治疗,对照组术后单用化疗.治疗结束后随访2年,评价2年无病生存率及总生存率.结果 观察组患者2年无病生存率及总生存率分别为66.0%、80.9%,均高于对照组的43.9%、61.0%,两组比较差异有统计学意义(P<0.05);观察组不良反应较对照组有所增加,但差异无统计学意义(P>0.05).结论 三维适形放疗联合化疗治疗进展期胃癌根治术后的患者能明显提高其2年无病生存率及总生存率,且不良反应无明显增加,患者耐受性较好.
目的 觀察同步放化療治療進展期胃癌根治術後患者的臨床療效和安全耐受性.方法 將96例根治術後的進展期胃癌患者隨機分為觀察組(52例)和對照組(44例).觀察組根治術後應用三維適形放療聯閤化療治療,對照組術後單用化療.治療結束後隨訪2年,評價2年無病生存率及總生存率.結果 觀察組患者2年無病生存率及總生存率分彆為66.0%、80.9%,均高于對照組的43.9%、61.0%,兩組比較差異有統計學意義(P<0.05);觀察組不良反應較對照組有所增加,但差異無統計學意義(P>0.05).結論 三維適形放療聯閤化療治療進展期胃癌根治術後的患者能明顯提高其2年無病生存率及總生存率,且不良反應無明顯增加,患者耐受性較好.
목적 관찰동보방화료치료진전기위암근치술후환자적림상료효화안전내수성.방법 장96례근치술후적진전기위암환자수궤분위관찰조(52례)화대조조(44례).관찰조근치술후응용삼유괄형방료연합화료치료,대조조술후단용화료.치료결속후수방2년,평개2년무병생존솔급총생존솔.결과 관찰조환자2년무병생존솔급총생존솔분별위66.0%、80.9%,균고우대조조적43.9%、61.0%,량조비교차이유통계학의의(P<0.05);관찰조불량반응교대조조유소증가,단차이무통계학의의(P>0.05).결론 삼유괄형방료연합화료치료진전기위암근치술후적환자능명현제고기2년무병생존솔급총생존솔,차불량반응무명현증가,환자내수성교호.
Objective To study the efficacy and safety of concurrent chemoradiotherapy on postoperative advanced gastric carcinoma.Methods Ninety-six patients with advanced gastric carcinoma after radical operation were randomly divided into observation group (52 cases) and control group (44 cases).Patients in observaotion group were treated by dimensional conformal radiotherapy combined with chemotherapy,and patients in control group were treated by chemotherapy alone.Two years followed-up was carried out after treatment,and the 2 years free progress time and overall survival rate was evaluated.Results Two years free progress time and overall survival rate in observation group were 66.0% and 80.9% respectively,both were higher than those in control group 43.9% and 61.0%,there were significant differences(P < 0.05) ; But the adverse reactions in observation group were more than those in control group,but the difference was not statistically significant(P > 0.05).Conclusions Concurrent chemoradiotherapy in treatment of post-operative advanced gastric carcinoma can improve the 2 years free progress time and overall survival rate,fail to produce more side effect,and is well tolerated by the patients.